Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis.
The present study was performed on 10 patients with severe adult respiratory distress syndrome (ARDS), all suffering from sepsis (mean lung injury score [LIS] (1): 3.25 +/- 0.1; duration of mechanical ventilation upon study entry: 3.1 +/- 0.6 d). Ex vivo analysis of the alveolar surfactant system, obtained by bronchoalveolar lavage (BAL), showed severe impairment of surfactant function. Three hundred milligrams of natural surfactant/kg body weight (Alveofact) was delivered bronchoscopically in separate doses to each segment of both lungs. This caused an immediate increase in PaO2/FlO2 from 85 +/- 7 mm Hg to 200 +/- 20 mm Hg (p < 0.001), mainly due to a decrease in shunt flow (42 +/- 4 to 20 +/- 2% [p < 0.001]). Reanalysis of the alveolar surfactant showed that its function was significantly improved. In five patients the increase in arterial oxygenation was partially lost within the next few hours, and a second dose of 200 mg/kg surfactant was applied 18 to 24 h later, again increasing PaO2/FlO2 values. Eight patients survived the subsequent 14-d observation period with progressive improvement of gas exchange, and five patients were definitely weaned from the respirator. All fatalities were due to non-respiratory causes. We conclude that the bronchoscopic application of a high dose of surfactant aimed at overcoming inhibitory factors in the alveolar space of these patients, may offer a feasible and safe approach to improving gas exchange in severe ARDS.
Walmrath
D
D
Department of Medicine, Justus-Liebig University, Giessen, Germany.
Günther
A
A
Ghofrani
H A
HA
Schermuly
R
R
Schneider
T
T
Grimminger
F
F
Seeger
W
W
D000293:Adolescent; D000328:Adult; D001999:Bronchoscopy; D005260:Female; D006439:Hemodynamics; D006801:Humans; D008055:Lipids / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010743:Phospholipids; D011652:Pulmonary Circulation; D011659:Pulmonary Gas Exchange; D011663:Pulmonary Surfactants / Q000008:administration & dosage*; D012128:Respiratory Distress Syndrome / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D015656:Respiratory Mechanics; D018805:Sepsis / Q000150:complications*; D014692:Ventilation-Perfusion Ratio
D008055:Lipids; D010743:Phospholipids; D011663:Pulmonary Surfactants; C078272:SF-RI 1, bovine surfactant preparation